Altered expression levels of HLA class Ⅱ and costimulatory molecules on circulating monocytes from patients with cervical intraepithelial neoplasia and squamous cervical cancer

Feng,Ting; Zhou,Jian-Hong; Liu,Jia; Ye,Feng; Lu,Weiguo; Xie,Xing

doi:10.3892/mmr.2012.1068

Altered expression levels of HLA class Ⅱ and costimulatory molecules on circulating monocytes from patients with cervical intraepithelial neoplasia and squamous cervical cancer

Authors:
- Ting Feng
- Jian-Hong Zhou
- Jia Liu
- Feng Ye
- Weiguo Lu
- Xing Xie
View Affiliations

Affiliations: Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, P.R. China, Central Laboratory, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, P.R. China
Published online on: September 10, 2012 https://doi.org/10.3892/mmr.2012.1068
Pages: 1301-1304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the role of the cell surface expression levels of HLA class I and II molecules, the costimulatory molecules CD80/B7-1 and CD86/B7-2, and the adhesion molecules CD54 and CD58 during cervical carcinogenesis. The expression levels of MHC class I and II molecules, the costimulatory molecules CD80/B7-1 and CD86/B7-2 and the adhesion molecules CD54 and CD58 on CD14+ peripheral blood monocytes (PBMs) from 21 cases of cervical intraepithelial neoplasia (CIN) II-III, 51 squamous cervical carcinomas (SCCs) and 18 healthy controls were analyzed using flow cytometry analysis. We found increased expression levels of HLA-DR (p=0.000), HLA-DQ (p=0.000), CD86/B7-2 (p=0.002) and CD58 (p=0.000) on PBMs from patients with SCC and CIN II-III, compared with healthy control subjects, whereas no significant difference existed in the expression levels of HLA class I antigens, HLA-DP CD80/B7-1 and CD54. Upregulated expression levels of HLA-DR, HLA-DQ, CD86/B7-2 and CD58 were associated with disease progression, indicating that an increased expression of HLA-DR, HLA-DQ, CD86/B7-2 and CD58 on PBMs may be correlated with the evolution of cervical cancer.

View Figures

View References

1	Moore MA and Tajima K: Cervical cancer in the asian pacific-epidemiology, screening and treatment. Asian Pac J Cancer Prev. 5:349–361. 2004.PubMed/NCBI
2	Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
3	Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A and Blay JY: The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today. 18:493–497. 1997. View Article : Google Scholar : PubMed/NCBI
4	Zhou JH, Ye F, Chen HZ, Zhou CY, Lu WG and Xie X: Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma. Life Sci. 78:2643–2649. 2006. View Article : Google Scholar : PubMed/NCBI
5	Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D and Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961–965. 1994. View Article : Google Scholar : PubMed/NCBI
6	Ardavin C, Martinez del Hoyo G, Martin P, et al: Origin and differentiation of dendritic cells. Trends Immunol. 22:691–700. 2001. View Article : Google Scholar : PubMed/NCBI
7	Fidler IJ and Kleinerman ES: Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol. 2:937–943. 1984.
8	Kleinerman ES, Ceccorulli LM, Bonvini E, Zicht R and Gallin JI: Lysis of tumor cells by human blood monocytes by a mechanism independent of activation of the oxidative burst. Cancer Res. 45:2058–2064. 1985.PubMed/NCBI
9	Ditschkowski M, Kreuzfelder E, Rebmann V, et al: HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg. 229:246–254. 1999. View Article : Google Scholar : PubMed/NCBI
10	Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D and Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 3:483–490. 1997.PubMed/NCBI
11	Pinzon-Charry A, Ho CS, Maxwell T, et al: Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer. 97:1251–1259. 2007. View Article : Google Scholar : PubMed/NCBI
12	Novellino PS, Trejo YG, Beviacqua M, Bordenave RH and Rumi LS: Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients. J Exp Clin Cancer Res. 18:481–484. 1999.PubMed/NCBI
13	Novellino PS, Trejo YG, Beviacqua M, Bordenave RH and Rumi LS: Regulation of HLA-DR antigen in monocytes from colorectal cancer patients by in vitro treatment with human recombinant interferon-gamma. J Investig Allergol Clin Immunol. 10:90–93. 2000.PubMed/NCBI
14	Woiciechowsky C, Asadullah K, Nestler D, et al: Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J Neuroimmunol. 84:164–171. 1998. View Article : Google Scholar : PubMed/NCBI
15	van Bokhorst-De van der Schuer MA, von Blomberg-van der Flier BM, Riezebos RK, et al: Differences in immune status between well-nourished and malnourished head and neck cancer patients. Clin Nutr. 17:107–111. 1998.PubMed/NCBI
16	Gebhard B, Gnant M, Schutz G, et al: Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. Anticancer Res. 20:4599–4604. 2000.PubMed/NCBI
17	Matsuoka T, Tabata H and Matsushita S: Monocytes are differentially activated through HLA-DR, -DQ, and -DP molecules via mitogen-activated protein kinases. J Immunol. 166:2202–2208. 2001. View Article : Google Scholar : PubMed/NCBI
18	Becker JC, Czerny C and Brocker EB: Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol. 6:1605–1612. 1994. View Article : Google Scholar : PubMed/NCBI
19	Wahl SM, McCartney-Francis N and Mergenhagen SE: Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today. 10:258–261. 1989. View Article : Google Scholar : PubMed/NCBI
20	Le Bouteiller P: HLA class I chromosomal region, genes, and products: facts and questions. Crit Rev Immunol. 14:89–129. 1994.PubMed/NCBI
21	Van Gool SW, Vandenberghe P, de Boer M and Ceuppens JL: CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev. 153:47–83. 1996.PubMed/NCBI
22	Harding FA, McArthur JG, Gross JA, Raulet DH and Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 356:607–609. 1992. View Article : Google Scholar : PubMed/NCBI
23	Girndt M, Sester M, Sester U, Kaul H and Kohler H: Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int. 59:1382–1389. 2001. View Article : Google Scholar : PubMed/NCBI
24	Zhu DM, Dustin ML, Cairo CW, Thatte HS and Golan DE: Mechanisms of cellular avidity regulation in CD2-CD58-mediated T cell adhesion. ACS Chem Biol. 1:649–658. 2006. View Article : Google Scholar : PubMed/NCBI